Copyright
©The Author(s) 2018.
World J Gastroenterol. Oct 28, 2018; 24(40): 4548-4553
Published online Oct 28, 2018. doi: 10.3748/wjg.v24.i40.4548
Published online Oct 28, 2018. doi: 10.3748/wjg.v24.i40.4548
Table 1 Regimens for second-line anti-Helicobacter pylori therapy
| Regimen | Drug | Duration of therapy | |||||
| PPI | Bismuth | Levo | Amox | Tetra | Metro | ||
| Bismuth-containing quadruple therapy | SD, b.i.d. | 120 mg, q.i.d. | 500 mg, q.i.d. | 500 mg, t.i.d. | 10-14 d | ||
| Levofloxacin-containing triple therapy | SD, b.i.d. | 500 mg, q.d. | 1 g, b.i.d. | 10-14 d | |||
| Levofloxacin-amoxicillin quadruple therapy | SD, b.i.d. | 120 mg, q.i.d. | 500 mg, q.d. | 1 g, b.i.d. | 10-14 d | ||
| Tetracycline-levofloxacin quadruple therapy | SD, b.i.d. | 120 mg, q.i.d. | 500 mg, q.d. | 500 mg, q.i.d. | 10 d | ||
| High-dose dual therapy | SD, q.i.d. | 750 mg, b.i.d. | 14 d | ||||
- Citation: Lin TF, Hsu PI. Second-line rescue treatment of Helicobacter pylori infection: Where are we now? World J Gastroenterol 2018; 24(40): 4548-4553
- URL: https://www.wjgnet.com/1007-9327/full/v24/i40/4548.htm
- DOI: https://dx.doi.org/10.3748/wjg.v24.i40.4548